TY  - JOUR

T1  - Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

JO  - Breast Cancer Research and Treatment

UR  - http://eprints.whiterose.ac.uk/133369/

PY  - 2018/05/04

AU  - Abraham J

AU  - Coleman R

AU  - Elias A

AU  - Holmes FA

AU  - Kalinsky K

AU  - Kittaneh M

AU  - Lower E

AU  - Mahtani R

AU  - Terry Mamounas E

AU  - Pegram M

AU  - Vogel C

ED  - 

DO  - DOI: 10.1007/s10549-018-4783-1

PB  - Springer Science and Business Media LLC

VL  - 171

IS  - 1

SP  - 11

EP  - 20

Y2  - 2025/10/10

ER  -